

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/B1D3663D3B8EN.html>

Date: December 2019

Pages: 1370

Price: US\$ 2,000.00 (Single User License)

ID: B1D3663D3B8EN

Abstracts

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide

covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 13, 78, 55, 1, 26, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages comprises 6, 4, 2, 1 and 4 molecules, respectively.

Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).

The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and

minor projects.

The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Bile Duct Cancer (Cholangiocarcinoma) - Overview

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment

Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics
Development

Bile Duct Cancer (Cholangiocarcinoma) - Drug Profiles

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects

Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products

Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AbbVie Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AbGenomics International Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ability Pharmaceuticals SL, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ABM Therapeutics Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Advenchen Laboratories LLC, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Alphamab Oncology, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Andes Biotechnologies, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Apollomics Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ascelia Pharma AB, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca Plc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BeiGene Ltd, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BioMed Valley Discoveries Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Co, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celldex Therapeutics Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellestia Biotech AG, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celltrion Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celon Pharma SA, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Clovis Oncology Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Coherent Biopharma, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

I would like to order

Product name: Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/B1D3663D3B8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B1D3663D3B8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970